Anindya Bhattacharya
Vice President, Head of Neuroscience Switch Therapeutics
Seminars
Friday 21st August 2026
Tissue & Cell Selective Conditionally Activated siRNA Targeting APOE & C1q
1:30 pm
- Outlining the design principles of switchable oligo platforms, including triple-stranded siRNA architectures that enable RNAi activity to be modulated or restricted based on cellular context
- Showcasing pipeline applications in neurodegenerative disease, including programs targeting APOE and C1q, to illustrate how cell-selective RNAi can be aligned with disease-relevant biology, and sparing target mediated AEs
